La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

NantHealth Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de NantHealth.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Healthcare Services croissance des bénéfices	30.8%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Investors Aren't Buying NantHealth, Inc.'s (NASDAQ:NH) Revenues

Apr 17

NantHealth GAAP EPS of -$0.11, revenue of $16.5M

Aug 04

Ronald Louks Is The Chief Operating Officer of NantHealth, Inc. (NASDAQ:NH) And They Just Sold 26% Of Their Shares

Mar 18

Time To Worry? Analysts Are Downgrading Their NantHealth, Inc. (NASDAQ:NH) Outlook

Mar 06

If You Had Bought NantHealth (NASDAQ:NH) Shares A Year Ago You'd Have Earned 183% Returns

Feb 04

NantHealth jumps after study highlights the utility of its decision-support platform

Dec 11

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme NantHealth n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

OTCPK:NHIQ - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2023	64	-70	-32	-28	N/A
6/30/2023	68	-69	-31	-25	N/A
3/31/2023	68	-64	-34	-28	N/A
12/31/2022	67	-68	-39	-32	N/A
9/30/2022	66	-59	-36	-31	N/A
6/30/2022	63	-56	-37	-31	N/A
3/31/2022	63	-59	-34	-29	N/A
12/31/2021	63	-58	-33	-28	N/A
9/30/2021	65	-62	-29	-23	N/A
6/30/2021	70	-62	-29	-23	N/A
3/31/2021	71	-95	-30	-24	N/A
12/31/2020	73	-88	-23	-17	N/A
9/30/2020	73	-81	-24	-18	N/A
6/30/2020	73	-86	-15	-10	N/A
3/31/2020	75	-55	-11	-7	N/A
12/31/2019	77	-65	-13	-9	N/A
9/30/2019	82	-101	-14	-10	N/A
6/30/2019	85	-183	-23	-15	N/A
3/31/2019	87	-188	-32	-21	N/A
12/31/2018	89	-190	-40	-30	N/A
9/30/2018	89	-164	-44	-34	N/A
6/30/2018	88	-89	-59	-50	N/A
3/31/2018	90	-125	-75	-68	N/A
12/31/2017	87	-131	-95	-81	N/A
9/30/2017	82	-157	-108	-92	N/A
6/30/2017	81	-161	N/A	-84	N/A
3/31/2017	80	-138	N/A	-65	N/A
12/31/2016	80	-145	N/A	-71	N/A
9/30/2016	83	-131	N/A	-74	N/A
6/30/2016	77	-128	N/A	-85	N/A
3/31/2016	66	-110	N/A	-91	N/A
12/31/2015	46	-62	N/A	-74	N/A
9/30/2015	48	-84	N/A	-63	N/A
6/30/2015	43	-91	N/A	-53	N/A
3/31/2015	39	-86	N/A	-47	N/A
12/31/2014	34	-84	N/A	-42	N/A
12/31/2013	27	-41	N/A	-16	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de NHIQ est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de NHIQ devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de NHIQ devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de NHIQ devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de NHIQ devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de NHIQ devrait être élevé dans 3 ans

NantHealth Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased to US$3.25

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall to -US$0.52

Analysts lower EPS estimates to -US$0.52

Price target lowered to US$3.75

Analysts lower EPS estimates to -US$0.55

Recent updates

NantHealth, Inc Appoints Scott Maratea as Chief Revenue Officer

NantHealth, Inc. Announces the Appointment of Marc Harrison as Chief Legal Officer

NantHealth, Inc. Files Form 15

NantHealth, Inc. Announces the Cessation of Ronald Louks as Chief Operating Officer

NantHealth, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

NantHealth, Inc. announced delayed 10-Q filing

Nanthealth, Inc. Announces Resignation of Deanna L. Wise from Her Position on the Board and as A Member of the Special Committee, the Audit Committee, and the Nominating and Corporate Governance Committee of the Board

Summus Holdings Engages in Discussions with NantHealth

NantHealth, Inc. Announces Executive Changes

Nant Capital Engages in Discussions with NantHealth

NantHealth, Inc. announced delayed 10-Q filing

NantHealth, Inc.(NasdaqGS:NH) dropped from S&P TMI Index

NantHealth Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Publicly Held Shares Requirement

First quarter 2023 earnings released: US$1.59 loss per share (vs US$2.07 loss in 1Q 2022)

NantHealth Receives Written Notice from Nasdaq Stating the Company Has Not Complied with the Public Float Requirement Prior to the Expiration of the Compliance Period

Investors Aren't Buying NantHealth, Inc.'s (NASDAQ:NH) Revenues

Full year 2022 earnings released: US$8.80 loss per share (vs US$7.66 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.094 loss in 3Q 2021)

NantHealth, Inc. to Report Q3, 2022 Results on Nov 03, 2022

NantHealth, Inc. Receives Written Notice from Nasdaq

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2021)

NantHealth GAAP EPS of -$0.11, revenue of $16.5M

NantHealth, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings: EPS misses analyst expectations

NantHealth, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$3.25

Consensus EPS estimates fall by 18%

NantHealth, Inc. Receives Notice from the Nasdaq Stock Market LLC

Full year 2021 earnings: EPS exceeds analyst expectations

NantHealth, Inc. to Report Q4, 2021 Results on Feb 24, 2022

NantHealth, Inc. Announces Not Stand for Re-Election of Michael S. Sitrick as Member of the Board Directors

Third quarter 2021 earnings released: US$0.094 loss per share (vs US$0.099 loss in 3Q 2020)

Chief Operating Officer notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.43 loss in 2Q 2020)

Consensus EPS estimates fall to -US$0.52

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.081 loss in 1Q 2020)

NantHealth, Inc. Launches Eviti Connect for Autoimmune Diseases

Founder recently bought US$5.0m worth of stock

NantHealth, Inc. announced that it expects to receive $137.5 million in funding from Nant Capital, LLC, Highbridge Capital Management, LLC

Ronald Louks Is The Chief Operating Officer of NantHealth, Inc. (NASDAQ:NH) And They Just Sold 26% Of Their Shares

Chief Operating Officer recently sold US$297k worth of stock

Time To Worry? Analysts Are Downgrading Their NantHealth, Inc. (NASDAQ:NH) Outlook

Analysts lower EPS estimates to -US$0.52

Full year 2020 earnings released: US$0.80 loss per share (vs US$0.57 loss in FY 2019)

Revenue and earnings miss expectations

NantHealth, Inc. to Report Q4, 2020 Results on Feb 25, 2021

If You Had Bought NantHealth (NASDAQ:NH) Shares A Year Ago You'd Have Earned 183% Returns

New 90-day high: US$4.07

NantHealth, Inc. and Sesame Announces Collaboration to Help Providers Increase Productivity and Better Serve Patients

New 90-day high: US$3.67

NantHealth Presents Significant Treatment Insights at the 2020 San Antonio Breast Cancer Symposium in a Time of Need with the Pandemic’s Impact on Cancer Care

NantHealth jumps after study highlights the utility of its decision-support platform

New 90-day high: US$2.81

Price target lowered to US$3.75

NantHealth, Inc. and ImmunityBio Announce RNA Profiling for Clinical Decision Support Publication In Nature’s Scientific Reports

Third quarter 2020 earnings released: US$0.099 loss per share

Revenue beats expectations, earnings disappoint

NantHealth, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: US$2.01

NantHealth, Inc. to Report Q2, 2019 Results on Aug 08, 2019

NantHealth, Inc. Enhances Interoperability of the Navinet Open Platform with Expanded API Capabilities

NantHealth, Inc. Rolls Out Navinet AllPayer Platform Nationally

New 90-day low: US$2.39

New 90-day low - US$2.60

Analysts lower EPS estimates to -US$0.55

First half earnings released

NantHealth, Inc. to Report Q2, 2020 Results on Aug 06, 2020

NantHealth, Inc. (NasdaqGS:NH) acquired The OpenNMS Group, Inc. Cambridge Equities, LP.